Research in contextEvidence before this studyA quarter of all strokes are lacunar in type with a high risk of cognitive decline, yet there are few trials of secondary prevention. Conventional secondary ischaemic stroke prevention after lacunar ischaemic stroke had limited benefit in preventing recurrent stroke, small vessel disease progression or cognitive decline. Licenced drugs which improve endothelial function, cilostazol or isosorbide mononitrate, may be effective but lack data in Western populations. In Asia-Pacific countries, cilostazol reduced recurrent stroke (five trials, 4780 patients, many with lacunar stroke, OR 0.64, 95%CI 0.51--0.79) and incident dementia (population registry analysis, 9148 dementia-free subjects, adjusted HR 0.75, 95%CI 0.61--0.92, p for dose trend, 0.001). There are no data on nitrates in secondary stroke prevention despite their widespread use in cardiovascular disease.Added value of this studyCilostazol and isosorbide mononitrate are well tolerated individually and together in patients with lacunar stroke, in addition to conventional secondary stroke prevention, may improve vascular function, cognitive and neuroimaging secondary outcomes.Implications of all the available evidenceLACI-1 supports wider testing of cilostazol and isosorbide mononitrate to prevent worsening of cerebral small vessel disease, a common cause of stroke, cognitive decline and dementia.Alt-text: Unlabelled Box

1. Introduction {#s0025}
===============

Cerebral small vessel disease (SVD) is a common cause of ischaemic ('lacunar') and haemorrhagic stroke, vascular and mixed dementias [@bb0005]. SVD is most commonly due to an intrinsic disorder of the brain\'s small perforating arterioles with endothelial dysfunction, blood--brain barrier leakage [@bb0010], impaired vasoreactivity and inflammation [@bb0005].

There is currently no specific secondary prevention for lacunar ischaemic stroke, or SVD-associated cognitive decline [@bb0015]. Dual antiplatelet therapy increased bleeding, and intensive antihypertensive treatment did not reduce recurrence [@bb0020], [@bb0025]. We identified two oral agents with potential modifying effects on the endothelial dysfunctions mentioned above, isosorbide mononitrate (ISMN) and cilostazol, from a detailed systematic literature analysis [@bb0015].

ISMN is a nitric oxide (NO) donor commonly used in angina. NO levels are reduced in acute and chronic stroke including lacunar stroke [@bb0030]. Glyceryl trinitrate (GTN), an NO donor, improved cognitive test scores at 90 days if given within 6 h of stroke [@bb0035]. NO has multiple potential effects which may benefit SVD, including improved blood--brain barrier integrity, vasodilation, reducing inflammation, and neuroprotection [@bb0015], [@bb0040]. However, data on ISMN in lacunar stroke are sparse since its main therapeutic indication, ischaemic heart disease, is uncommon in these patients [@bb0045].

Cilostazol is a phosphodiesterase 3′ inhibitor [@bb0015] used for peripheral vascular disease in Europe and North America [@bb0050], and stroke prevention in Asia-Pacific countries where there are data from trials including over 6000 patients showing reduction in recurrent stroke [@bb0055]. Cilostazol also has multiple potential benefits relevant to SVD, including improving blood--brain barrier integrity, vasodilation, reducing inflammation, and neuroprotection [@bb0015], [@bb0060]. In a large national health registry in Taiwan, prescription of cilostazol was associated with reduced incidence of dementia [@bb0065].

There is little experience of cilostazol in lacunar stroke outside the Asia-Pacific Region, of ISMN in lacunar stroke anywhere, or of the drugs in combination, yet the effects are potentially synergistic [@bb0015]. The aims of the LACunar Intervention Trial-1 (LACI-1) trial were to test ISMN and cilostazol, alone and combined, for tolerability including symptoms, safety, and signals for efficacy (cognitive, systemic, cerebrovascular and haematological endpoints) after lacunar ischaemic stroke. LACI-1 tested short-term drug administration including dose escalation to prepare for a larger trial of longer-term drug administration with safety and efficacy outcomes.

2. Materials and Methods {#s0030}
========================

LACI-1 was a Phase IIa, partial factorial, dose-escalation, prospective, randomised, open-label, blinded endpoint (PROBE) trial conducted in two large UK stroke centres (Edinburgh and Nottingham). The trial was approved by the Scotland A Research Ethics Committee (Ref 15/SS/0154), the Medicines and Healthcare Regulatory Agency (Ref 01384/0244/001-0001) and NHS R + D (Ref 2015/0354/TMF) and all participants gave written informed consent. There were no changes to the methods after trial commencement.

The trial was registered: ISRCTN-12580546, [ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0005} ([NCT02481323](NCT02481323){#ir0010}), EudraCT (2015-001953-33). The Protocol and Statistical Analysis Plan are published [@bb0070]. LACI-1 reporting follows the CONSORT statement.

The first participant was recruited and randomised on 16th March 2016, the final patient on 29th August 2017 and final follow-up was competed on 31 October 2017.

2.1. Patient Selection {#s0035}
----------------------

We included patients with: clinical lacunar stroke in the past four years with brain magnetic resonance imaging (MRI) or CT scanning obtained at the presentation with stroke showing a symptomatic small subcortical (lacunar) infarct (\< 20 mm), or (if no recent relevant infarct was visible), that excluded other causes of symptoms (e.g. acute cortical infarct, tumour); age ≥ 35 years; were independent in activities of daily living (modified Rankin Scale of ≤ 2); and had capacity to give informed consent [@bb0070]. An acute small subcortical infarct was defined on CT as a \< 20 mm diameter hypoattenuated area (relative to the brain, but not as hypoattenuated as CSF) in white or deep grey matter, in a brain region corresponding with the stroke symptoms, not present on neuroimaging (if available) prior to the stroke.

We excluded patients with: other active neurological illness since the incident stroke; cognitive impairment (Montreal Cognitive Assessment \[MoCA\] score below 20); active cardiac disease; symptomatic carotid artery stenosis \> 50% requiring urgent treatment; definite contraindication to or indication for either trial drug; taking prohibited medications that could not be changed (anticoagulants, phosphodiesterase 5′ inhibitors, macrolides, ketoconazole, itraconazole, omeprazole); creatinine clearance \< 25 ml/min; bleeding tendency or a history of intracranial haemorrhage; or inability to swallow [@bb0070].

2.2. Data Collection at Baseline {#s0040}
--------------------------------

We collected baseline demographic, clinical and cognitive characteristics, including minimisation variables of age ≤/\>70 years, local investigator-determined SVD severity on brain scanning (SVD score ≤/\>2) [@bb0075], systolic blood pressure ≤/\>140 mm Hg and time after stroke ≤/\>100 days, prior to randomisation.

2.3. Randomisation and Masking {#s0045}
------------------------------

We used a secure web-based randomisation system, hosted at the University of Nottingham, to randomise participants 1:1:1:1 into four groups (CONSORT Diagram, [Fig. 1](#f0005){ref-type="fig"}). We used minimisation on age, SVD score, systolic BP, time since onset to maintain balance in baseline variables between the groups, and switching 5% of randomisations randomly to an alternate treatment group, to reduce predictability:1)cilostazol alone, 50 mg twice daily, increasing to 100 mg twice daily;2)ISMN alone, 25 mg once daily increasing to 25 mg twice daily;3)cilostazol and ISMN combined, started immediately, ISMN given first; and.4)cilostazol and ISMN combined, start delayed for three weeks, cilostazol given first.Fig. 1CONSORT diagram.ISMN = isosorbide mononitrate.Fig. 1

Participants allocated to both drugs aimed to attain the same target doses as for either drug alone. Group four (delayed start, both drugs) provided a 'no drug' comparison during the first three weeks of the trial while they received no drug.

To maintain blinding of participants, prior to the start of the trial, the Investigational Supplies Group (ISG), an independent arm of the Research and Development Office, NHS Lothian, removed study medications from their original blister packs and placed them in bottles labelled 'Drug A' or 'Drug B', a process which was approved by the Medicines and Healthcare Regulatory Agency. The labelled bottles were distributed to the hospital pharmacies at the City Hospital, Nottingham and the Western General Hospital, Edinburgh for storage and dispensing to participants following randomisation.

The randomisation program provided a prescription detailing the number of bottles of 'Drug A' and/or 'Drug B', which was dispensed by the hospital pharmacy with instructions about dose escalation and a diary for the participant to record their actual doses. The instructions referred to 'Drug A' or 'Drug B', not to either drug by name.

Trial medication was taken for nine weeks, starting at low dose and increasing gradually over 2--3 weeks, as tolerated, to full dose, sustained until eight weeks post-randomisation, then decreased and stopped over one week, with a final follow-up after two further weeks without trial tablets [@bb0070]. We designed the escalating dose to reduce potential adverse effects during cilostazol initiation (recommended where cilostazol is more widely used in Asia-Pacific countries), and escalation is standard for ISMN. Nine weeks allowed time for dose escalation and a period on sustained dose to evaluate tolerability since data were insufficient to move directly to a trial with longer term administration. Patients returned unused tablets to pharmacy for counting and destruction. Participants continued to take their prescribed medications, including conventional stroke prevention drugs, during the trial.

2.4. Outcomes {#s0050}
-------------

The primary outcome was the proportion of participants achieving target dose by the end of the eight-week trial period, assessed by structured questionnaire, by staff masked to allocated group. Secondary outcomes, in all participants, also by staff masked to allocated group, were: symptoms (headache, nausea, diarrhoea, vomiting, bleeding) recorded by structured questionnaire on alternate weeks; safety, (systemic or intracranial bleeding, recurrent vascular events, death); blood pressure, measured sitting and standing at study visits; heart rate; Trails A and B tests for cognitive function; systemic arterial stiffness (pulse wave analysis using the SphygmoCor tonometry device \[Atcor Medical\]); and platelet function (P-selectin flow cytometry) [@bb0080]. Participants recruited in Edinburgh also had MR brain imaging at randomisation using the Blood Oxygen Level Dependent (BOLD) method to assess cerebrovascular reactivity (CVR) to a challenge of 6% CO~2~ in inspired air in white and deep grey matter, using a validated technique [@bb0085] (full details of CVR acquisition and analysis are in the Supplementary material). The CVR examination was repeated after three weeks of no drug in the delayed start group, and at the end of the eight-week treatment period in the other three groups, to assess if the trial treatments altered CVR. The repeat structural scanning also allowed us to test for alterations in white matter lesions (WML), lacunes or microbleeds between baseline and the end of the trial.

We performed central blinded reading of the diagnostic CT and MRI imaging to score the index infarct, SVD features and total SVD score [@bb0075], using structured, validated tools [@bb0090]. We also assessed the structural MR brain images, performed as part of the CVR examination, for change in SVD lesions, new infarcts or haemorrhages occurring during the trial [@bb0090].

2.5. Statistical Analysis and Power {#s0055}
-----------------------------------

We powered the LACI-1 trial to test the hypothesis that patients would tolerate one drug better than both drugs, setting the sample size to detect a difference of 90% versus 55% (i.e. an absolute difference of 35%) between those reaching target (full) dose on one drug versus both drugs. For 80% power, significance 0.05, a sample size of 55 was needed; therefore, we aimed to recruit 60 participants (for sample size estimation for the CVR substudy, please see the Supplementary material p3) [@bb0070].

In primary and secondary analyses, we compared outcomes by treatment allocation to test cilostazol versus no cilostazol, ISMN versus no ISMN, and both drugs versus one drug with the delayed start group providing a drug-free control period. We calculated odds ratios (ORs) for tablet compliance by allocated group using binary logistic regression with adjustment for minimisation factors (age, SVD score, systolic blood pressure and time from stroke to randomisation in days). We assessed secondary outcomes of symptoms, safety, cognitive and physiological measures in all, and change in CVR and in SVD lesions in patients recruited in Edinburgh, using binary logistic regression for binary variables, multiple linear regression for continuous variables, Kruskal--Wallis test for between group differences in continuous variables since the variables were not normally distributed, and refer to mean differences (MD) where relevant. We also examined time trends over the 11 weeks of the trial in repeated measures analysis comparing delayed versus immediate start of both drugs. All analyses were on intention to treat, except we performed an additional secondary analysis of change in CVR by proportion of target dose achieved.

3. Role of the Funding Source {#s0060}
=============================

The trial was designed, conducted, analysed, interpreted, the paper written and submitted independently of the funders.

4. Results {#s0065}
==========

Recruitment into LACI-1 began on 16th March 2016 and ended on 29th August 2017, and we randomised 57 patients, 29 in Nottingham and 28 in Edinburgh ([Fig. 1](#f0005){ref-type="fig"}), rate 1.64 patients/centre/month (Supplementary Fig. S1). The mean age was 66.1 (SD 11.1) years, 18 were female (32%), the median time from index stroke to randomisation was 203 days, 42 (74%) had hypertension, and 26 (46%) were current smokers ([Table 1](#t0005){ref-type="table"}). Most participants (55, 97%) were taking clopidogrel for secondary stroke prevention and two (3%) were taking aspirin. Most participants (80%) had a visible index infarct on their diagnostic imaging (MRI in 44 (77%) and CT in 13 (23%) participants, some had both), and 25 (44%) had moderate to severe WML.Table 1Baseline characteristics of patients randomised in LACI-1.Table 1AllBoth delayedISMNCilostazolBoth immediatePatients (number)5715151314Age (years)[⁎](#tf0005){ref-type="table-fn"}66.1 (11.1)63.4 (11.5)62.2 (11.0)75.8 (8.7)64.4 (8.1)Sex, female18 (31.6%)6 (40.0%)4 (26.7%)5 (38.5%)3 (21.4%)Onset to randomisation (days)202.6 (256.2)153.3 (180.4)137.5 (214.2)279.2 (324.7)254.0 (290.7)Systolic BP (mm Hg)147.3 (20.5)141.8 (19.6)150.9 (19.0)146.1 (21.3)150.4 (22.9)Diastolic BP (mm Hg)83.3 (12.6)82.9 (14.3)86.6 (11.5)79.3 (12.0)83.7 (12.6)Past medical history (%) Treated hypertension42 (73.7%)11 (73.3%)11 (73.3%)12 (92.3%)8 (57.1%) Treated hyperlipidaemia48 (84.2%)11 (73.3%)12 (80.0%)13 (100.0%)12 (85.7%) Diabetes11 (19.3%)3 (20.0%)3 (20.0%)2 (15.4%)3 (21.4%) Atrial fibrillation00000 Ipsilateral carotid stenosis \> 50%1 (3.1%)001 (14.3%)0 Myocardial infarction or angina3 (5.3%)2 (13.4%)01 (7.7%)0 Previous stroke or TIA8 (14.0%)2 (13.4%)2 (13.3%)2 (15.4%)2 (14.3%) Smoking26 (45.6%)10 (66.7%)6 (40.0%)6 (46.2%)4 (28.6%) Alcohol intake \[units per week\]1.0 \[0.0, 7.0\]1.0 \[0.0, 5.0\]1.0 \[0.0, 7.0\]1.0 \[0.0, 9.0\]3.5 \[0.0, 10.0\]Patient status mRS, baseline \[/6\]1.0 \[0.0, 1.0\]1.0 \[0.0, 2.0\]1.0 \[1.0, 1.0\]1.0 \[1.0, 1.0\]1.0 \[0.0, 1.0\] Current NIHSS \[/42\]0.0 \[0.0, 1.0\]0.0 \[0.0, 1.0\]0.0 \[0.0, 1.0\]0.0 \[0.0, 1.0\]0.5 \[0.0, 1.0\]Cognition MoCA (/30)25.8 (2.4)25.5 (2.9)27.0 (1.7)25.2 (2.2)25.4 (2.6) TMT part B (secs)101.1 (74.7)84.9 (44.2)77.0 (32.3)141.1(101.5)107.3 (93.3) TMT part B (points)[⁎](#tf0005){ref-type="table-fn"}23.5 (4.1)24.7 (0.7)24.3 (0.9)21.2 (6.9)23.4 (4.5) NART (error score)18.0 (12.7)16.8 (9.2)14.3 (9.7)20.4 (16.1)21.0 (15.2)Investigator reported scan information SVD score MRI (/4)1.2 (1.0)1.6 (1.3)0.9 (0.6)1.0 (0.0)1.3 (1.3) SVD score CT (/2)0.9 (0.8)0.7 (0.8)0.9 (0.7)1.3 (0.9)0.8 (0.8)Centrally adjudicated scan information Scan type, MRI44 (77.2%)13 (86.7%)14 (93.3%)7 (53.8%)10 (71.4%) Visible acute stroke lesion MRI36 (81.8%)9 (69.2%)11 (78.6%)6 (85.7%)10 (100.0%) SVD score MRI (/4)1.8 (1.2)1.9 (1.2)1.4 (1.2)2.1 (0.7)2.1 (1.5) ≥ 1 lacune27 (61.4%)10 (76.9%)6 (42.9%)4 (57.1%)7 (70.0%) ≥ 1 microbleeds7 (17.9%)2 (18.2%)1 (7.7%)1 (16.7%)3 (33.3%) Perivascular spaces26 (59.1%)7 (53.8%)8 (57.1%)5 (71.4%)6 (60.0%) WML Fazekas MRI19 (43.2%)6 (46.2%)4 (28.6%)4 (57.1%)5 (50.0%)Scan type, CT13 (22.8%)2 (13.3%)1 (6.7%)6 (46.2%)4 (28.6%)Visible acute stroke lesion CT10 (76.9%)2 (100.0%)1 (100.0%)4 (66.7%)3 (75.0%)Side of brain, left5 (50.0%)1 (50.0%)1 (100.0%)1 (25.0%)2 (66.7%)SVD score CT (/2)0.9 (0.9)0.5 (0.7)1.0 (--)1.5 (0.8)0.3 (0.5) ≥ 1 lacune6 (46.2%)01 (100.0%)4 (66.7%)1 (25.0%) WML Fazekas CT[⁎](#tf0005){ref-type="table-fn"}6 (46.2%)1 (50.0%)05 (83.3%)0[^2][^3]

The groups were well balanced for baseline characteristics except for the participants allocated to cilostazol who were older, had higher Fazekas scores indicating more WML, and had lower Trails B scores respectively ([Table 1](#t0005){ref-type="table"}). One participant withdrew at week three (delayed start dual drugs, prior to receiving any trial drug) and did not complete that follow-up or any after; one participant missed a follow-up in week five (ISMN group) but completed all prior and subsequent follow-ups.

4.1. Tablet Compliance {#s0070}
----------------------

For the primary outcome, 40 (72%) were taking full (no doses missed) or partial doses (includes missing between one and up to 50% of allocated dose) of the allocated tablets by the end of the eight-week treatment period, with no difference between groups ([Table 2](#t0010){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}; partial dose details, Supplementary Fig. S2). Most patients who achieved 'partial dose' only missed one or two doses in any assessment period. ISMN may be tolerated better than cilostazol: 13/15 allocated ISMN alone (87%) achieved full or partial ≥ 50% dose by week eight versus 9/13 (69%) allocated cilostazol alone (any ISMN versus no ISMN achieving full dose, OR 3.77, 95%CI 0.98--14.46, p = 0.053; any cilostazol versus no cilostazol achieving full dose, OR 0.39, 95%CI 0.11--1.34, p = 0.14). Dual drugs were tolerated similarly to either individual drug: ISMN plus cilostazol versus one or other drug alone achieving full dose, OR 0.84, 95%CI 0.27--2.64, p = 0.77 ([Table 2](#t0010){ref-type="table"}). Combining the full and partial doses versus no tablets gave similar results (data not shown). In the dual drug groups, there was no evidence that starting with one drug produced different symptoms or tolerance than starting with the other drug, or that those who ceased to take tablets did so because of more symptoms.Table 2Outcomes at week 8. All analyses are adjusted for baseline age, mean SBP, time from onset to randomisation and SVD total. Adjustment for other baseline covariates is included where stated. For SVD total, the central scan readings were used and MRI was chosen over CT if both were available.Table 2Both delayed\
N = 14ISMN\
N = 15Cil\
N = 13Both immediate\
N = 14Cilostazol vs. no Cil\
(2 + 3 v 1 + 4[a](#tf0010){ref-type="table-fn"})ISMN vs. no ISMN\
(1 + 3 v 2 + 4[a](#tf0010){ref-type="table-fn"})Cil + ISMN vs. Cil alone or ISMN alone\
(3 + 4 v 1 or 2)Week 3\
(4[a](#tf0010){ref-type="table-fn"})Week 8\
(4)Week 8\
(1)Week 8\
(2)Week 8\
(3)OR/MD\
(95%CI)p-ValueOR/MD\
(95%CI)p-ValueOR/MD\
(95%CI)p-ValuePrimary outcomeOn target dose week 8 (%)NA5 (35.7%)8 (53.3%)3 (23.1%)5 (35.7%)0.39 (0.11, 1.34)0.1363.77 (0.98, 14.46)0.0530.84 (0.27, 2.64)0.769On partial dose (≥ 1/2 tablets) week 8 (%)NA4 (28.6%)5 (33.3%)6 (46.2%)4 (28.6%)1.68 (0.48, 5.83)0.4140.49 (0.13, 1.79)0.2800.51 (0.15, 1.71)0.277On partial dose (\< 1/2 tablets) week 8 (%)NA2 (14.3%)003 (21.4%)2.37 (0.31, 18.33)0.4081.40 (0.18, 11.00)0.748NCNCTaking no tablets on week 8 (%)NA3 (21.4%)2 (13.3%)4 (30.8%)2 (14.3%)1.00 (0.19, 5.22)0.9970.26 (0.04, 1.46)0.1250.86 (0.19, 3.92)0.847  Secondary outcomesPatients with symptom Headache (%)3 (21.4%)4 (28.6%)4 (26.7%)1 (7.7%)1 (7.1%)0.29 (0.05, 1.76)0.1780.93 (0.18, 4.81)0.9281.26 (0.26, 6.18)0.774 Nausea (%)1 (7.1%)3 (21.4%)1 (6.7%)2 (15.4%)3 (21.4%)5.07 (0.58, 44.42)0.1431.24 (0.18, 8.74)0.8282.81 (0.51, 15.34)0.234 Loose stools (%)5 (35.7%)4 (28.6%)02 (15.4%)4 (28.6%)1.43 (0.35, 5.88)0.6230.39 (0.08, 1.90)0.2427.07 (1.07, 46.66)0.042 Bleeding (%)2 (14.3%)03 (20.0%)2 (15.4%)2 (14.3%)1.05 (0.18, 6.26)0.9590.36 (0.06, 2.29)0.2810.25 (0.03, 1.98)0.189Peripheral haemodynamics, adjusted for baseline Systolic (mm Hg), mean (SD)134.8 (12.4)131.4 (19.0)144.1 (16.5)146.7 (19.4)139.9 (20.7)− 1.1 (− 8.4, 6.2)0.77− 1.1 (− 8.5, 6.4)0.78− 4.9 (− 11.7, 1.9)0.16 Average of systolic & diastolic (mm Hg), mean (SD)107.6 (10.6)104.7 (14.0)114.5 (11.1)114.0 (13.2)109.9 (14.7)− 1.1 (− 6.3, 4.1)0.67− 0.7 (− 6.0, 4.6)0.79− 3.6 (− 8.4, 1.2)0.14 Diastolic (mm Hg), mean (SD)80.4 (9.7)78.0 (10.8)84.9 (7.6)81.3 (11.2)79.8 (10.5)− 1.6 (− 5.8, 2.6)0.45− 0.7 (− 5.0, 3.7)0.77− 2.6 (− 6.5, 1.4)0.20 Heart rate (bpm), mean (SD)74.3 (9.3)79.5 (11.2)74.7 (12.5)80.6 (15.0)84.8 (15.1)6.4 (1.2, 11.7)0.020.1 (− 5.5, 5.6)0.983.1 (− 1.9, 8.2)0.23Platelet function, adjusted for baseline ADP median fluorescence, mean (SD)519.3 (234.5)502.1 (242.8)454.9 (238.8)518.9 (179.5)451.7 (176.5)− 1.3 (− 77.6, 75.0)0.97− 0.5 (− 80.1, 79.1)0.9911.9 (− 60.2, 84.1)0.75 AA median fluorescence, mean (SD)741.0 (395.0)775.4 (474.4)675.2 (364.1)636.4 (272.4)679.6 (376.6)− 83.6 (− 256.5, 89.4)0.34− 14.1 (− 192.5, 164.2)0.88109.7 (− 54.0, 273.5)0.19 Unstimulated median fluorescence, mean (SD)87.0 (29.0)80.4 (29.1)86.1 (29.0)75.9 (27.3)83.7 (33.8)− 2.9 (− 15.1, 9.3)0.64− 8.2 (− 20.7, 4.2)0.207.5 (− 4.0, 19.0)0.20 Hb (g/L), week 8, adjusted for baseline, mean (SD)133.0 (12.2)136.2 (13.5)146.9 (12.0)130.8 (9.5)137.1 (14.6)− 3.7 (− 8.4, 1.0)0.12− 1.0 (− 6.9, 4.4)0.73− 2.4 (− 6.8, 2.1)0.30 Platelet count, week8, adjusted for baseline, mean (SD)260.3 (47.1)258.4 (56.1)238.6 (45.5)289.5 (61.4)284.3 (57.8)35.7 (2.8, 68.7)0.033.9 (− 32.4, 40.2)0.83− 7.4 (− 36.8, 21.9)0.62Central arterial pressure waveform analysis, adjusted for baseline Pulse wave velocity m/s, mean (SD)16.8 (7.5)23.2 (11.9)18.6 (11.3)17.9 (8.1)18.6 (8.5)− 0.4 (− 5.1, 4.4)0.891.1 (− 3.7, 5.9)0.66− 0.8 (− 5.3, 3.6)0.72 Pulse wave analysis Augmentation index 75 (%), mean (SD)24.0 (10.6)16.2 (12.4)17.5 (12.9)23.0 (10.6)14.7 (10.5)− 4.8 (− 9.7, 0.2)0.06− 4.7 (− 9.8, 0.3)0.070.1 (− 4.8, 4.9)0.97 Central blood pressure, mean (SD)99.0 (14.6)95.4 (12.7)101.2 (12.4)103.1 (11.8)98.8 (11.7)− 2.0 (− 8.2, 4.2)0.52− 4.7 (− 10.7, 1.2)0.12− 3.4 (− 9.1, 2.4)0.25 Buckberg viability ratio, mean (SD)154.4 (21.5)164.8 (22.2)166.6 (25.2)152.2 (31.4)132.9 (22.7)− 10.8 (− 21.2, − 0.5)0.046.8 (− 4.0, 17.1)0.20− 11.4 (− 21.0, − 1.7)0.02Cognition (TMT), adjusted for baseline TMT A --- time, mean (SD)39.5[a](#tf0010){ref-type="table-fn"} (15.1)37.8 (16.8)33.5 (10.3)51.1 (33.5)31.9 (9.2)− 4.0 (− 12.7, 4.7)0.37− 4.2 (− 12.8, 4.4)0.34− 5.6 (− 13.4, 2.3)0.17 TMT A --- points, mean (SD)24.9[a](#tf0010){ref-type="table-fn"} (0.4)23.1 (6.7)25.0 (0.0)21.2 (9.4)24.9 (0.3)− 1.1 (− 3.6, 1.5)0.412.6 (0.1, 5.1)0.050.3 (− 2.1, 2.7)0.81 TMT B --- time, mean (SD)84.9[a](#tf0010){ref-type="table-fn"} (44.2)79.9 (34.4)76.9 (39.4)114.3 (63.1)84.3 (50.4)− 3.4 (− 22.7, 16.0)0.73− 3.1 (− 22.4, 16.3)0.76− 2.3 (− 20.2, 15.6)0.80 TMT B --- points, mean (SD)24.7[a](#tf0010){ref-type="table-fn"} (0.7)22.9 (6.6)24.7 (0.8)19.4 (9.3)22.9 (4.1)− 2.2 (− 5.1, 0.7)0.142.3 (− 0.7, 5.3)0.13− 0.2 (− 3.0, 2.60)0.89[^4][^5]Fig. 2Tablet compliance: Proportion of participants who were taking full dose combined with the proportion taking ≥ 1/2 tablets into one group, (solid lines, labelled 'full dose') noting that missing even one dose was counted as ≥ 1/2 tablets). The combined and delayed groups from week 5 onwards had very close numbers and so the lines appear on top of each other. The dotted lines show those who had taken no tablets at all that week. More details of compliance by number of missed doses is given in Fig. S2. ISMN = isosorbide mononitrate.Fig. 2

4.2. Symptoms Potentially Related to Trial Medication {#s0075}
-----------------------------------------------------

Symptoms were common without trial medication. In the week prior to randomisation, the following symptoms were experienced: headache 30%; palpitations 20%; dizziness 40%; loose stools 30%; nausea 15%; dyspepsia 45%; bruising 20%; bleeding from mucous membranes 15%; and rash 9%. Following drug initiation, there was a slight increase in headache, palpitations, dizziness, loose stools, nausea, followed by a return to baseline levels with continued trial drug ([Fig. 3](#f0015){ref-type="fig"}; [Table 2](#t0010){ref-type="table"}; Supplementary Fig. S3). There was no increase in dyspepsia, bruising, or bleeding (Supplementary Fig. S3). Neither cilostazol nor ISMN were associated with more symptoms and patients allocated dual drugs did not report more symptoms than those allocated one drug ([Fig. 3](#f0015){ref-type="fig"}; [Table 2](#t0010){ref-type="table"}; Supplementary Fig. S3).Fig. 3Symptoms of headache, palpitations, dizziness, loose stools, and nausea. ISMN = isosorbide mononitrate.Fig. 3

4.3. Secondary Outcomes, All Participants {#s0080}
-----------------------------------------

[Cognition]{.ul}: The points achieved on Trails A increased in the group allocated to ISMN compared with no ISMN (MD 2.6, 95%CI 0.1, 5.1, p = 0.045), with no effect on Trails B points (MD 2.3, 95%CI − 0.7, 5.3, p = 0.126) after adjustment for baseline Trails ([Table 2](#t0010){ref-type="table"}). Participants took less time to complete the tests in groups allocated cilostazol versus no cilostazol, ISMN versus no ISMN, and both versus one or other drug, although these differences did not reach significance.

[Blood pressure]{.ul} (BP) reduced during drug initiation, but with no significant difference between groups by week eight ([Table 2](#t0010){ref-type="table"}). Heart rate at week eight was higher in those allocated cilostazol versus no cilostazol (MD 6.4, 95%CI 1.2--11.7, p = 0.017). Buckberg Index (subendocardial perfusion) was reduced at week eight with cilostazol (OR − 10.87, 95%CI − 21.2, − 0.5, p = 0.04) and combined cilostazol and ISMN (OR − 11.4, 95%CI − 21.0, − 1.7, p = 0.02). There were no sustained changes in pulse wave velocity or Augmentation Index.

[Haematology]{.ul}: There was no difference in haemoglobin or platelet function between groups at the end of the treatment period ([Table 2](#t0010){ref-type="table"}). However, platelet count increased in those on cilostazol vs no cilostazol (MD 35.7 95%CI 2.8, 68.7, p = 0.033).

4.4. Adverse Events, All Participants {#s0085}
-------------------------------------

There were ten Serious Adverse Events (SAEs), six mild and four of moderate severity, three possibly and the rest definitely or probably not related to trial drugs (Supplementary Tables S1 and S2). There was one recurrent ischaemic stroke in the 'dual drugs immediate' group and one TIA in the ISMN group. There were no deaths or major haemorrhages and no SAEs in the cilostazol group.

4.5. Cerebrovascular Reactivity and SVD Lesion Change, Participants in Edinburgh {#s0090}
--------------------------------------------------------------------------------

Of 28 participants randomised in Edinburgh, one chose not to participate in the MRI sub-study, one did not complete MRI due to claustrophobia and two received insufficient CO~2~ challenge due to problems with gas delivery, leaving 24 participants with complete CVR data to assess change. The groups were well balanced for demographic and neuroimaging characteristics (Supplementary Table S3), with mean age 67.5 (range 53--83) and 13/24 were male (56%).

CVR increased more between baseline and follow-up in those allocated cilostazol or ISMN compared with those allocated delayed start (who were taking no drug at the follow-up CVR examination) although the difference was not significant (Kruskal--Wallis, p = 0.18), [Fig. 4](#f0020){ref-type="fig"}a. Final CVR values were higher in participants taking any versus no trial drug ([Fig. 4](#f0020){ref-type="fig"}b) although the difference was not significant (Kruskal--Wallis, p = 0.16).Fig. 4Cerebrovascular reactivity (CVR). a) Change in white matter CVR by allocated treatment group (difference between groups, Kruskal--Wallis, p = 0.18). b) Change in white matter CVR in participants taking half target dose or greater of any allocated treatment versus those taking no or less than half dose (difference between groups, Kruskal--Wallis, p = 0.16).Fig. 4

Compared with baseline, the T2/FLAIR structural MRI at follow-up showed a decline in WML in participants allocated cilostazol (WML reduced in 5/12 participants) versus no cilostazol (no change), Chi-square p = 0.007. In participants allocated to ISMN, WML reduced in 3/13 versus in 2/13 in participants allocated to no ISMN, Chi-square p = 0.62. In addition, one microbleed disappeared in a participant allocated to ISMN and two lacunes appeared, both in participants allocated 'dual drugs immediate start'.

5. Discussion {#s0095}
=============

LACI-1 tested short-term administration of cilostazol and ISMN, alone and in combination, in patients with lacunar ischaemic stroke. The drugs and doses were well-tolerated and dose escalation was feasible. Most participants, including those in the dual drug groups, were taking target, or near to target dose, by the end of the treatment period. Symptoms such as headache, palpitations, nausea were common both off and on, either or both, trial medications, with no evidence of sustained increase in symptoms on target dose, or of any difference between groups allocated single or dual drugs. There were no drug-related adverse events or bleeding complications, despite all participants also taking prescribed antiplatelet drugs. The nitrate donor ISMN and the phosphodiesterase 3′ inhibitor cilostazol act on relevant target mechanisms [@bb0015] based on current knowledge of human sporadic SVD [@bb0005], and are licenced agents with established safety profiles. LACI-1 showed that both drugs affect systemic haemodynamic function, and may improve vasoreactivity in white matter, reduce WML, and improve cognitive performance, all of which require confirmation in larger trials. LACI-1 demonstrates drug tolerability and supports testing of ISMN and cilostazol in larger trials with clinical endpoints.

Data on nitrates in patients with lacunar stroke, or other SVD manifestations, are limited [@bb0045]. In the Efficacy of Nitric Oxide in Stroke (ENOS) Trial, seven days of GTN improved cognitive test scores at 90 days if started within 6 h of acute stroke [@bb0035], lowered BP and its variability in acute lacunar syndromes, and improved early neurological outcome in those with a confirmed acute lacunar infarct. NO donors could improve vasoreactivity (which is impaired in lacunar stroke [@bb0095]), are neuroprotective and anti-inflammatory [@bb0015], all relevant targets in SVD [@bb0005]. Such effects could explain improvements in WML, cognition, systemic haemodynamics and cerebral vasoreactivity suggested in LACI-1 and are worth testing in larger trials. Alternatively, the reduction in WML seen in some patients could reflect the modest blood pressure reduction seen in the trial, although whether such effects could occur in a few weeks is unknown. Data on other vasoactive drugs in SVD are limited. In post-hoc analyses, patients who experienced headache soon after starting dipyridamole for secondary stroke prevention had fewer recurrent strokes than those without headache [@bb0100], suggesting that headache may be a useful indicator of improved cerebrovascular reactivity which may help prevent further stroke.

Trials testing cilostazol for secondary stroke prevention include over 6000 patients in Korea, Japan or China, but focused on short-term stroke prevention after ischaemic stroke [@bb0055], with limited data on symptoms or tolerance rates and only one small study on platelet function [@bb0105]. Cilostazol has weak antiplatelet effects and therefore low bleeding risk [@bb0110]. Trials testing cilostazol to prevent cognitive decline are ongoing [@bb0115], and routinely prescribed cilostazol was associated with fewer incident dementias in a large Taiwanese health data registry, in a 'dose response' manner [@bb0065]. Short-term cilostazol improved cerebrovascular pulsatility [@bb0120]. There are no data on tolerance or stroke prevention in Western populations and limited data in peripheral vascular disease [@bb0050]. Differences in SVD prevalence, diet, lifestyle and risk factor exposures preclude direct generalisation from Asia-Pacific to Western populations [@bb0125]. In experimental models, cilostazol unblocks endothelial-dysfunction induced oligodendrocyte precursor cell maturation, thus improving myelin formation and repair and sustaining axons [@bb0130], reduces oxidative stress, attenuates microglial activation and WML formation [@bb0135], [@bb0140], and improves amyloid-β clearance [@bb0145]. These pleiotropic effects would be beneficial if translated to human sporadic SVD, and could explain improvements in cognition, cerebrovascular reactivity and reduction in WML suggested in LACI-1 and should be tested in future trials.

5.1. Limitations {#s0100}
----------------

LACI-1 limitations include its small size, short-term drug administration and limited clinical endpoints. The size limited analysis of whether drug effects differed by lacunar clinical syndrome, but could be tested in future trials. We used the Trails A and B tests of cognitive function which may be prone to practice effects but this will affect all uses of these standard tests. The minimisation algorithm was imperfect since there was a baseline imbalance in age, reflected in the WML and cognitive scores. The combined drugs were better tolerated than expected. There was no formal 'no drug' control group throughout the trial, although there was the 'drug-free period' in the 'dual drug, delayed start' group. There were no previous data available on initiation of both drugs together, therefore for dual administration, we integrated the dose escalation usually used for each drug. Slow dose escalation of dipyridamole and aspirin did not reduce headache, in comparison with standard dose escalation, although may have improved adherence [@bb0150]. Since the doses for licenced indications are somewhat arbitrary and wide ranging, it is reasonable to think that half dose would have some effect on the target mechanisms, and can be tested a priori in larger trials. Patients could enter the trial with CT or MRI brain imaging, thus achieving faster recruitment at lower expense than just using MRI, while ensuring generalisability. We estimate that the trial would have taken eight months (50%) longer and cost £85,000 (33%) extra with mandatory MRI. The flexible imaging entry criteria did not allow assessment of causes of lacunar stroke such as branch atheromatous disease; this could be assessed in future trials, but requirement for detailed MRI might reduce recruitment.

5.2. Conclusions {#s0105}
----------------

LACI-1 suggests that patients can be randomised to ISMN and cilostazol in addition to guideline secondary stroke prevention including single antiplatelet agents. LACI-1 indicates that LACI-2 (ISRCTN14911850), a partial-factorial prospective randomised open-label blinded endpoint trial, aiming to randomise 400 patients, should proceed, to assess these medications\' effects on stroke recurrence, cognitive function, neuropsychiatric symptoms, progression of SVD and safety in patients with lacunar stroke, and feasibility for large definitive trial.
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